The way forward in HCV treatment — finding the right path

@article{Manns2007TheWF,
  title={The way forward in HCV treatment — finding the right path},
  author={Michael P. Manns and Graham R Foster and J{\"u}rgen K. Rockstroh and Stefan Zeuzem and Fabien Zoulim and Michael Houghton},
  journal={Nature Reviews Drug Discovery},
  year={2007},
  volume={6},
  pages={991-1000}
}
Infection with the hepatitis C virus (HCV) represents an important health-care problem worldwide. The prevalence of HCV-related disease is increasing, and no vaccine is yet available. Since the identification of HCV as the causative agent of non-A, non-B hepatitis, treatment has progressed rapidly, but morbidity and mortality rates are still predicted to rise. Novel, more efficacious and tolerable therapies are urgently needed, and a greater understanding of the viral life cycle has led to an… 
HCV NS5B polymerase inhibitors.
therapy Hepatitis C virus entry: possible targets for
TLDR
This work has used viral antigen to screen for reactivity with patient-derived antibodies in hepatitis C virus and identified non-A non-B hepatitis (NANB), a major cause of liver disease.
Immunotherapy for HCV infection: next steps
TLDR
Treatment issues combined with new concepts in immune therapy serve to underscore an urgent need for the development of improved immunotherapies, such as novel interferons, and support the possible development of therapeutic vaccines for the treatment of chronic HCV infection.
Second-wave protease inhibitors: choosing an heir.
Viral Hepatitis B and C. Cure or Treatment?
TLDR
Talking about HCV treatment today equals to talking about total cure of the patient, with treatments of very high SVR rates, shorter if not shortest duration, minimal risk for resistance, pangenotypic and practically with no serious adverse events, no fibrosis or previous treatment status limitations, but also with a very high cost.
Treatment of hepatitis C virus infection with interferon and small molecule direct antivirals: viral kinetics and modeling.
TLDR
Current knowledge of HCV kinetics under IFN-based therapy and newly developed antiviral agents specifically targeted to attack HCV are reviewed, and how mathematical models have helped to improve the understanding ofHCV infection and treatment are shown.
Review Nucleotide prodrugs for HCV therapy
TLDR
The identification of several prodrugs of nucleoside 5′-monophosphates that are potent inhibitors of HCV replication in vitro have progressed into the clinic and the early data demonstrate greatly reduced viral load levels in HCV-infected patients.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 105 REFERENCES
Hepatitis C therapeutics: current status and emerging strategies
TLDR
The development of effective HCV antiviral therapeutics continues to be a daunting challenge owing to the absence of adequate animal models and tissue-culture systems for analysis and propagation of the virus.
Challenges and successes in developing new therapies for hepatitis C
TLDR
Preclinical evidence is accumulating that development of resistance will eventually limit the efficacy of new drugs, and combinations of multiple agents will be required to treat chronic HCV infection.
An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus
TLDR
Administration of BILN 2061 to patients infected with HCV genotype 1 for 2 days resulted in an impressive reduction of HCV RNA plasma levels, and established proof-of-concept in humans for an HCV NS3 protease inhibitor, illustrating the potential of the viral-enzyme-targeted drug discovery approach for the development of new HCV therapeutics.
Treating viral hepatitis C: efficacy, side effects, and complications
TLDR
The efficacy and optimisation of the current standard therapy of hepatitis C and its problems in special patient populations are described.
Future Therapies for Hepatitis C
TLDR
This review focuses on four classes of new agents: new interferons, ribavirin-like molecules, specific small-molecule hepatitis C virus inhibitors and new immune therapies, with particular emphasis on medications in the later stages of development.
Review HCV Antiviral Resistance: The Impact of in vitro Studies on the Development of Antiviral Agents Targeting the Viral NS5B Polymerase
TLDR
HCV sub-genomic replicons have been used to study viral resistance to both nucleoside and non-nucleoside NS5B inhibitors and suggest that drug-resistant viruses are likely to evolve in vivo.
Understanding hepatitis C.
  • J. McHutchison
  • Medicine, Biology
    The American journal of managed care
  • 2004
TLDR
Increases in HCV-related end-stage liver disease and HCC will have significant implications for clinicians and pharmacists in managed care settings over the next 2 decades are reviewed.
Epidemiology of Hepatitis C Virus (HCV) Infection
TLDR
Current hepatitis C virus prevalence and genotype data are reviewed and the different risk factors associated with the virus are examined and the current risk factors are examined.
Structural biology of hepatitis C virus
TLDR
Structural analyses of HCV components provide an essential framework for understanding of the molecular mechanisms ofHCV polyprotein processing, RNA replication, and virion assembly and may contribute to a betterUnderstanding of the pathogenesis of hepatitis C.
...
1
2
3
4
5
...